Graft versus Leukemia in 2023.
Best Pract Res Clin Haematol
; 36(3): 101476, 2023 09.
Article
en En
| MEDLINE
| ID: mdl-37611995
ABSTRACT
Allogeneic hematopoietic stem cell transplantation (HSCT) is commonly utilized in the management of leukemia across multiple subtypes. Graft versus leukemia (GVL) is a critical component of successful transplantation and involves donor cells eradicating residual leukemia within the recipient. Graft versus host disease (GVHD) by contrast is a common complication of the transplantation process in which donor cells identify the recipient's various organ systems as foreign, thereby leading to a multitude of organ toxicities that can be described as autoimmune in nature. As both GVL and GVHD are mediated by a similar mechanism, these processes are felt to occur in tandem with one another. Here, we review the allogeneic HCT process in the context of GVL.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Leucemia
/
Trasplante de Células Madre Hematopoyéticas
/
Enfermedad Injerto contra Huésped
Límite:
Humans
Idioma:
En
Revista:
Best Pract Res Clin Haematol
Asunto de la revista:
HEMATOLOGIA
Año:
2023
Tipo del documento:
Article